Minerva Neurosciences, Inc. (NERV) EPS Estimated At $-0.43; Nuveen New York Select Tax-free Income Portfolio (NXN) Has 1.5 Sentiment

February 18, 2018 - By Adrian Mccoy

Analysts expect Minerva Neurosciences, Inc. (NASDAQ:NERV) to report $-0.43 EPS on March, 12.They anticipate $0.16 EPS change or 59.26% from last quarter’s $-0.27 EPS. After having $-0.28 EPS previously, Minerva Neurosciences, Inc.’s analysts see 53.57% EPS growth. The stock decreased 0.91% or $0.05 during the last trading session, reaching $5.45. About 130,971 shares traded. Minerva Neurosciences, Inc. (NASDAQ:NERV) has risen 56.56% since February 18, 2017 and is uptrending. It has outperformed by 39.86% the S&P500.

The stock 0.01% or $0 during the last trading session, reaching $12.9. It is down 2.33% since February 18, 2017 and is downtrending. It has underperformed by 19.03% the S&P500.

Tortoise Investment Management Llc holds 0.32% of its portfolio in Nuveen New York Select Tax-Free for 74,074 shares. Next Financial Group Inc owns 3,330 shares or 0.01% of their US portfolio. Moreover, Invesco Ltd. has 0% invested in the company for 54,317 shares. The New York-based Morgan Stanley has invested 0% in the stock. Royal Bank Of Canada, a Ontario – Canada-based fund reported 3,000 shares.

Among 3 analysts covering Minerva Neurosciences (NASDAQ:NERV), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Minerva Neurosciences had 5 analyst reports since March 9, 2016 according to SRatingsIntel. JMP Securities maintained Minerva Neurosciences, Inc. (NASDAQ:NERV) on Wednesday, March 9 with “Market Outperform” rating. The firm earned “Buy” rating on Thursday, June 22 by Jefferies. On Friday, September 1 the stock rating was initiated by Citigroup with “Buy”. On Friday, May 27 the stock rating was maintained by Jefferies with “Buy”. Jefferies reinitiated it with “Buy” rating and $10 target in Thursday, May 12 report.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company has market cap of $210.92 million. The company's lead product candidate includes MIN-101, a compound for the treatment of patients with schizophrenia that completed Phase IIb clinical trial. It currently has negative earnings. It also offers MIN-202, which completed Phase IIa clinical trial for treating primary insomnia, as well as completed Phase 1b used for the treatment of major depressive disorder; and MIN-117, a compound that completed Phase IIa clinical trial for the treatment of patients suffering from major depressive disorder.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>